dsRNA: Why Polymerase Choice Matters

Double-stranded RNA formation during in vitro transcription reduces mRNA manufacturing efficiency and can trigger immune responses in therapeutic applications. Addressing dsRNA at its source—rather than relying on downstream purification—offers a more sustainable manufacturing strategy.

RNA polymerase behavior is central to this challenge. Enzyme performance during initiation, promoter clearance, and elongation determines whether transcription yields clean mRNA or costly byproducts. Independent evaluation shows how engineered polymerases reduce dsRNA formation while preserving transcript integrity and yield across varied conditions.

As self-amplifying RNA and longer constructs tighten downstream processing windows, polymerase selection becomes a meaningful process design lever. Data reveals measurable differences in dsRNA-to-mRNA ratios, capping efficiency, and purity profiles between enzyme variants—demonstrating why polymerase choice deserves strategic consideration as mRNA programs scale toward commercial manufacturing.